uniQure NV's stock surged 6.87% during Tuesday's intraday trading session, following news of a leadership change at the U.S. Food and Drug Administration.

The biotech company's shares rose as FDA Commissioner Marty Makary plans to resign, according to reports. This development comes after the FDA in March had called for a new study to support the approval of uniQure's gene therapy for a rare neurodegenerative disorder and rejected its most recent trial design.

Investors appear to be interpreting the regulatory leadership transition as potentially creating new opportunities for uniQure's gene therapy program, which has faced recent FDA challenges. The market reaction suggests optimism about possible shifts in regulatory approach under new leadership.